Mumbai: Ahead of the rollout of the shortest treatment for drug-resistant TB, called BPaL, Indian doctors published a study proving that halving the d.
This regimen includes a new anti-TB drug, namely Pretomanid, in combination with Bedaquiline & Linezolid (with/without Moxifloxacin). Pretomanid has earlier been approved and licenced for use in India ...
India's fight against Multi-Drug-Resistant Tuberculosis (MDR-TB) has received new ammunition with the Centre giving nod for the shorter and safer BPaLM regimen (bedaquiline, pretomanid, linezolid, and ...